Faculty profile

Zach Walsh

ResearcherMedicineUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Zach Walsh

Researcher

Medicine

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
27 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Harm Reduction People Who Use Drugs Cannabis Cannabis Access Cannabis Use Drug-Related Harm Gateway Effects Legalization

Latest papers

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days.
Psychopharmacology · 2026 · senior author
The Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose-Response.
Journal of psychoactive drugs · 2026 · senior author
Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis.
Journal of cannabis research · 2026

All 67 publications

Latest funding

Longitudinally evaluating the health impacts of cannabis regulation among two sentinel populations with high rates of cannabis use and drug-related harms
CIHR · 2022 · Principal investigator
$490,845
Evaluating tetrahydrocannabinol as an adjunct to opioid agonist therapy for individuals living with opioid use disorder: A Phase II, placebo-controlled, blinded, pilot study to assess safety and feasibility
CIHR · 2020 · Co-investigator
$279,224
Investigating cannabis as harm reduction during a community-wide overdose crisis
CIHR · 2018 · Principal investigator
$125,000

All 8 grants and awards

67 publications.

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days.

St Pierre M, Argento E, Cates J, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Paschall SA, Kuypers KPC, Rootman J, Walsh Z

Psychopharmacology2026Senior author

DOI: 10.1007/s00213-025-06913-9 PMID: 41073618

The Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose-Response.

St Pierre M, Squires S, Daniels S, Sanchez T, Walsh Z

Journal of psychoactive drugs2026Senior author

DOI: 10.1080/02791072.2025.2449932 PMID: 39781623

Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis.

McAdam E, Reddon H, Socías ME, Lake S, Hayashi K, DeBeck K, Walsh Z, Milloy MJ

Journal of cannabis research2026

DOI: 10.1186/s42238-026-00458-0 PMID: 42343486

Medical Cannabis Use Adjunct to Standard of Care in a Residential Substance Use Recovery Program: A Pilot Study.

Fehr FC, Lo LA, Nelson CC, Diehl L, Walsh Z

Journal of studies on alcohol and drugs2025Senior author

DOI: 10.15288/jsad.24-00224 PMID: 39927474

Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.

Pierre MS, Standing L, Herman Y, Haden M, Walsh Z

Psychedelic medicine (New Rochelle, N.Y.)2024Senior author

DOI: 10.1089/psymed.2023.0060 PMID: 40051688

"This is you teaching you:" Exploring providers' perspectives on experiential learning and enhancing patient safety and outcomes in ketamine-assisted therapy.

Argento E, Petker T, Vig J, Robertson C, Jaeger A, Necyk C, Thielking P, Walsh Z

PloS one2024Senior author

DOI: 10.1371/journal.pone.0306381 PMID: 39208303

Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.

Bell AD, MacCallum C, Margolese S, Walsh Z, Wright P, Daeninck PJ, Mandarino E, Lacasse G, Kaur Deol J, de Freitas L, St Pierre M, Belle-Isle L, Gagnon M, Bevan S, Sanchez T, Arlt S, Monahan-Ellison M, O'Hara J, Boivin M, Costiniuk C

Cannabis and cannabinoid research2024

DOI: 10.1089/can.2021.0156 PMID: 36971587

Stigma-related barriers to medical cannabis as harm reduction for substance use disorder: Obstacles and opportunities for improvement.

Fehr F, Lo LA, Nelson C, Nanson K, Diehl L, Nielson K, Reddon H, Walsh Z

International journal of mental health nursing2024Senior author

DOI: 10.1111/inm.13231 PMID: 37767954

Cannabis use to manage stimulant cravings among people who use unregulated drugs.

Reddon H, Socias ME, DeBeck K, Hayashi K, Walsh Z, Milloy MJ

Addictive behaviors2024

DOI: 10.1016/j.addbeh.2023.107867 PMID: 37748225

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R

Psychopharmacology2024

DOI: 10.1007/s00213-024-06666-x PMID: 39126501

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Harm Reduction Dear Professor Walsh, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Longitudinally evaluating the health impacts of cannabis regulation among two sentinel populations with high rates of cannabis use and drug-related harms" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Zach Walsh

Research

Latest papers

Latest funding

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days.

The Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose-Response.

Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis.

Medical Cannabis Use Adjunct to Standard of Care in a Residential Substance Use Recovery Program: A Pilot Study.

Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.

"This is you teaching you:" Exploring providers' perspectives on experiential learning and enhancing patient safety and outcomes in ketamine-assisted therapy.

Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions.

Stigma-related barriers to medical cannabis as harm reduction for substance use disorder: Obstacles and opportunities for improvement.

Cannabis use to manage stimulant cravings among people who use unregulated drugs.

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Frequent collaborators

Kanna Hayashi

Kanna Hayashi

Pamela Kryskow

Jane Buxton

Thomas Kerr

Hudson Reddon

Cecilia Costiniuk

Shari Margolese

Marilou Gagnon

Evan Wood

Cecilia Costiniuk

Kora DeBeck

Shannon Dames

Nadia Fairbairn

Jacob Karsh

Rebecca Haines-Saah

Gina Martin

Nadia Fairbairn

Sergio Rueda

Gerald Thomas

Michael-John Milloy

Adrian Guta

Andreas Laupacis

Kate Shannon

Brian Bird

Benedikt Fischer

Carol Strike

Hani El-Gabalawy